www.fdanews.com/articles/189029-plexbios-lung-cancer-panel-gains-ce-mark
![](https://www.fdanews.com/ext/resources/test/Drug-Images/lungs.gif?t=1434439204&width=430)
PlexBio’s Lung Cancer Panel Gains CE Mark
November 2, 2018
Taiwanese diagnostics manufacturer PlexBio has received the CE Mark for its IntelliPlex lung cancer panel, used for identifying DNA mutations.
The assay can recognize 36 DNA mutations, including ones in the KRAS, NRAS, PIK3CA, BRAF and EGFR genes, and 19 gene rearrangements of ALK, ROS1, RET, NTRK1 and MET genes.
It can use Plexbio’s πCode technology, a circular disk that can create more than 16,000 image patterns for use in multiplexing.